BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24243636)

  • 1. A paradigm shift in the monitoring of patients with acromegaly: last available growth hormone may overestimate risk.
    Sherlock M; Reulen RC; Aragon-Alonso A; Ayuk J; Clayton RN; Sheppard MC; Hawkins MM; Bates AS; Stewart PM
    J Clin Endocrinol Metab; 2014 Feb; 99(2):478-85. PubMed ID: 24243636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GH and mortality in acromegaly.
    Sheppard MC
    J Endocrinol Invest; 2005; 28(11 Suppl International):75-7. PubMed ID: 16625851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly.
    Sherlock M; Aragon Alonso A; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):74-81. PubMed ID: 19178529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.
    Ayuk J; Clayton RN; Holder G; Sheppard MC; Stewart PM; Bates AS
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1613-7. PubMed ID: 15070920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IGF-I and mortality in patients with acromegaly.
    Strasburger CJ
    J Endocrinol Invest; 2005; 28(11 Suppl International):78-80. PubMed ID: 16625852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
    Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
    J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
    Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
    Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment.
    Campana C; Cocchiara F; Corica G; Nista F; Arvigo M; Amarù J; Rossi DC; Zona G; Ferone D; Gatto F
    J Clin Endocrinol Metab; 2021 Mar; 106(3):789-801. PubMed ID: 33236108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
    Freda PU; Post KD; Powell JS; Wardlaw SL
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excess mortality in acromegaly.
    Holdaway IM
    Horm Res; 2007; 68 Suppl 5():166-72. PubMed ID: 18174739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic.
    Mercado M; Gonzalez B; Vargas G; Ramirez C; de los Monteros AL; Sosa E; Jervis P; Roldan P; Mendoza V; López-Félix B; Guinto G
    J Clin Endocrinol Metab; 2014 Dec; 99(12):4438-46. PubMed ID: 25210882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.
    Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Florimonte L; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1999 Jan; 84(1):17-23. PubMed ID: 9920056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
    Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels.
    Feelders RA; Bidlingmaier M; Strasburger CJ; Janssen JA; Uitterlinden P; Hofland LJ; Lamberts SW; van der Lely AJ; de Herder WW
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6480-9. PubMed ID: 16159936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly.
    Holdaway IM; Bolland MJ; Gamble GD
    Eur J Endocrinol; 2008 Aug; 159(2):89-95. PubMed ID: 18524797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic tests and basal values for defining active acromegaly.
    Tzanela M
    Neuroendocrinology; 2006; 83(3-4):200-4. PubMed ID: 17047383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment.
    Colao A; Terzolo M; Bondanelli M; Galderisi M; Vitale G; Reimondo G; Ambrosio MR; Pivonello R; Lombardi G; Angeli A; degli Uberti EC
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):613-20. PubMed ID: 18410555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
    Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
    Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.